Agilent Technologies’ (NYSE:A) “Overweight” Rating Reaffirmed at Morgan Stanley

Morgan Stanley restated their overweight rating on shares of Agilent Technologies (NYSE:A) in a research note released on Tuesday, November 14th, MarketBeat.com reports.

A number of other analysts have also issued reports on the company. Bank of America reaffirmed an equal weight rating on shares of Agilent Technologies in a research report on Tuesday, August 15th. BidaskClub lowered Agilent Technologies from a strong-buy rating to a buy rating in a report on Monday, July 31st. Deutsche Bank set a $68.00 price objective on Agilent Technologies and gave the company a buy rating in a report on Wednesday, August 16th. Goldman Sachs Group reissued a neutral rating and issued a $68.00 price objective on shares of Agilent Technologies in a report on Tuesday, September 26th. Finally, J P Morgan Chase & Co restated an overweight rating and issued a $70.00 target price on shares of Agilent Technologies in a research note on Wednesday, August 16th. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $68.34.

Agilent Technologies (NYSE A) traded down $0.55 during mid-day trading on Tuesday, hitting $68.69. The stock had a trading volume of 2,516,520 shares, compared to its average volume of 1,938,537. Agilent Technologies has a 1-year low of $43.27 and a 1-year high of $70.93. The company has a quick ratio of 2.85, a current ratio of 3.30 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $22,106.37, a PE ratio of 28.98, a price-to-earnings-growth ratio of 2.08 and a beta of 1.27.

Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.05. Agilent Technologies had a return on equity of 16.96% and a net margin of 15.30%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter last year, the firm earned $0.59 earnings per share. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. sell-side analysts forecast that Agilent Technologies will post 2.58 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be issued a $0.149 dividend. The ex-dividend date of this dividend is Friday, December 29th. This represents a $0.60 annualized dividend and a dividend yield of 0.87%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. Agilent Technologies’s dividend payout ratio is currently 25.24%.

In other news, CFO Didier Hirsch sold 1,200 shares of the company’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $66.00, for a total value of $79,200.00. Following the transaction, the chief financial officer now directly owns 164,202 shares of the company’s stock, valued at $10,837,332. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Patrick Kaltenbach sold 5,000 shares of the company’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $69.56, for a total transaction of $347,800.00. Following the completion of the transaction, the insider now directly owns 75,504 shares in the company, valued at $5,252,058.24. The disclosure for this sale can be found here. Insiders sold 151,114 shares of company stock worth $10,359,388 in the last ninety days.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jennison Associates LLC bought a new stake in Agilent Technologies in the second quarter worth $212,000. Commerce Bank bought a new stake in Agilent Technologies during the second quarter valued at about $1,242,000. Delta Lloyd Asset Management N.V. bought a new stake in Agilent Technologies during the second quarter valued at about $2,026,000. Prudential Financial Inc. boosted its holdings in Agilent Technologies by 2.5% during the second quarter. Prudential Financial Inc. now owns 457,503 shares of the medical research company’s stock valued at $27,134,000 after acquiring an additional 11,020 shares during the period. Finally, Cipher Capital LP boosted its holdings in Agilent Technologies by 18.1% during the second quarter. Cipher Capital LP now owns 89,523 shares of the medical research company’s stock valued at $5,309,000 after acquiring an additional 13,703 shares during the period.

TRADEMARK VIOLATION NOTICE: “Agilent Technologies’ (NYSE:A) “Overweight” Rating Reaffirmed at Morgan Stanley” was posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://baseballnewssource.com/markets/agilent-technologies-inc-a-earns-overweight-rating-from-morgan-stanley/1783169.html.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.